Review Article Stem Cell Therapy in Stargardt Disease: A Systematic Review Atousa Moghadam Fard1, MD; Reza Mirshahi1, MD; Masood Naseripour2, MD; Khalil Ghasemi Falavarjani2, MD 1Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran 2Stem Cell and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran ORCID: Khalil Ghasemi Falavarjani: https://orcid.org/0000-0001-5221-1844 Atousa Moghadam Fard: https://orcid.org/0000-0003-2763-1577 Abstract This article aimed to review current literature on the safety and efficacy of stem cell therapy in Stargardt disease. A comprehensive literature search was performed, and two animal and eleven human clinical trials were retrieved. These studies utilized different kinds of stem cells, including human or mouse embryonic stem cells, mesenchymal stem cells, bone marrow mononuclear fraction, and autologous bone marrow-derived stem cells. In addition, different injection techniques including subretinal, intravitreal, and suprachoroidal space injections have been evaluated. Although stem cell therapy holds promise in improving visual function in patients with Stargardt disease, further investigation is needed to determine the long-term benefits, safety, and efficacy in determining the best delivery method and selecting the most appropriate stem cell type. Keywords: Juvenile-Onset Macular Degeneration; Juvenile-Onset Macular Dystrophy; Stargardt Disease; Stem Cell; Stem Cell Therapy J Ophthalmic Vis Res 2023; 18 (3): 318–327 INTRODUCTION Stargardt macular dystrophy, also known as Stargardt disease, is the most common form of inherited autosomal recessive macular dystrophy in humans, with a prevalence of 1 in 10/000 people.[1–3] Stargardt diseases causes juvenile- onset bilateral progressive vision loss. The disease occurs due to macular retinal pigment epithelium (RPE) atrophy and photoreceptor loss, which starts from the foveal and para-foveal areas.[4] Correspondence to: Khalil Ghasemi Falavarjani, MD. Eye Research Center, Rassoul Akram Hospital, Sattarkhan Niayesh St., Tehran 14553, Iran. Email: drghasemi@yahoo.com Received: 20-08-2022 Accepted: 26-01-2023 Access this article online Website: https://knepublishing.com/index.php/JOVR DOI: 10.18502/jovr.v18i3.13780 Stargardt disease is caused by mutations in the ATP-Binding Cassette subfamily A, member 4 (ABCA4) gene (also known as ABCR), which is located in the short arm of chromosome 1 in the majority of cases.[5] Although Stargardt diseases is a monogenic disease, because of multiple mutations (different variants of ABCA4), there is heterogeneity in the age of onset of the disease and variations in clinical presentations.[6–8] Currently, there is no FDA-approved therapy for Stargardt disease. Several approaches, including stem cell therapy, gene therapy, complement This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite this article: Moghadam Fard A, Mirshahi R, Naseripour M, Falavarjani KG. Stem Cell Therapy in Stargardt Disease: A Systematic Review. J Ophthalmic Vis Res 2023;18:318–327. 318 © 2023 Moghadam Fard et al. THIS IS AN OPEN ACCESS ARTICLE DISTRIBUTED UNDER THE CREATIVE COMMONS ATTRIBUTION LICENSE | PUBLISHED BY KNOWLEDGE E http://crossmark.crossref.org/dialog/?doi=10.18502/jovr.v18i3.13780&domain=pdf&date_stamp=2019-07-17 https://knepublishing.com/index.php/JOVR Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al inhibitors, and visual cycle modulators, have been proposed for the treatment of Stargardt disease.[9, 10] Several studies are in the preclinical or early clinical phases to determine the safety and efficacy of treatment modalities.[9, 11] Stem cell therapy is one of the promising approaches on the horizon for the treatment of retinal dystrophies. Stem cells are able to differentiate into various kinds of cell types to replace lost or damaged cells.[12] Several studies have been conducted to determine the safety and efficacy of stem cell therapy for Stargardt disease.[13–25] In addition, various stem cell types and delivery methods have been studied.[13–25] In this article, studies reporting stem cell therapy for the treatment of Stargardt disease were reviewed. METHODS The present study was designed based on the guidelines of Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).[26] A comprehensive literature search was performed on MEDLINE/PubMed and Scopus databases on November 20, 2022, without a time limitation; with the following search strategy: (Stargardt OR Stargardt’s OR juvenile-onset macular degeneration OR juvenile-onset macular dystrophy) AND (stem cell OR stem-cell). Reviews and non-English articles were excluded. All original studies that evaluated stem cell therapy in Stargardt disease were included in this systematic review. Articles were reviewed to include studies on Stargardt disease caused by ABCA4 mutations. All the mentioned processes of the search and screening were performed by two independent investigators (AMF, RM). Any disagreement was resolved by discussion. If an agreement could not be reached, the disagreement was resolved by a third investigator who was an expert in the study field (KGF). The quality of evidence for the studies which were finally included was assessed using the Grading of Recommendations, Assessment, and Evaluation (GRADE) approach developed by the Cochrane Collaboration. In this system, the randomized clinical trials (RCTs) start the assessment process as high quality (four stars) and non-RCTs start with a low-quality score (two stars). Afterward, based on risk of bias, inconsistency, indirectness, imprecision, and publication bias, the study is downgraded. In rare instances, it is upgraded in case of large effect, dose response, or no plausible confounding.[27] RESULTS The initial literature search revealed 179 articles. Finally, a total of 13 articles, including 2 animal and 11 human studies, met our inclusion criteria and were included in this review [Figure 1]. In total, 95 eyes from 78 human participants were treated by stem cells [Table 1]. Among the 11 human studies, 7 reported the use of human embryonic stem cells (hESC),[13, 14, 16, 19, 21–23] 2 reported the use of autologous bone marrow-derived stem cells,[15, 20] 1 reported the use of adipose tissue-derived mesenchymal stem cells (MSCs),[18] and 1 reported the use of bone marrow mononuclear fraction with CD34+ cells.[17] The delivery method in human studies was subretinal[13, 14, 16, 19–23] in eight articles, intravitreal[17] in one, suprachoroidal[18] in one, and a mix of methods including retrobulbar, subtenon, intravitreal, subretinal, and intravenous[15] in one study. Complications among human studies included the occurrence of small subretinal hemorrhage at the injection site in two eyes, mild vitreous cavity hemorrhage in one eye, retinal detachment in two eyes, high postoperative intraocular presser in two eyes, acute vitreous culture-positive endophthalmitis (Staphylococcus Epidermidis) in one eye, and cataract in three eyes. Furthermore, one eye experienced proliferative vitreoretinopathy. In addition, in one eye with a high dosage of stem cell injection, localized retinal thinning and decreased sensitivity in the hyperpigmentation area was reported. Stem cell treatment led to significant improvement in visual acuity in 38 eyes as compared to the fellow untreated eyes. The quality of evidence was assessed as very low for all included studies as none of them were RCTs. In addition, the low sample size number and lack of independent analysis were important factors in determining the final quality score. Therefore, due to the bias induced by these factors, the final score was downgraded in all studies to the lowest possible quality score. JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 319 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al DISCUSSION The results of this review show that stem cell therapy holds promise in improving visual function for Stargardt disease. With stem cell therapy, the visual acuity improved significantly in 38 eyes out of 95 treated eyes. No tumor formation, teratoma formation, differentiation of stem cell into ectopic cells, or immune rejection of the transplanted tissue was found. The most reported adverse events following stem cell therapy in Stargardt patients were hemorrhage (subretinal and vitreous cavity), retinal detachment, cataract, and high postoperative intraocular pressure. Stargardt disease is a progressive, autosomal recessive disease which is caused by mutations in the ABCA4 gene, an ATP-Binding Cassette transport gene superfamily member, which contains 50 exons and is on the short arm of chromosome number one (1P).[5, 19, 28, 29] The ABCA4 gene is localized to the rod and cone photoreceptors; the gene encodes the retina- specific transmembrane protein that has a role in recycling the 11-cis-retinal. Disruption of this cycle leads to lipofuscin accumulation, which is toxic to the RPE cells.[33–35] Progressive bilateral atrophy of the RPE cells in Stargardt disease occurs due to the accumulation of lipofuscin.[36] Parmar et al[37] found that bis-retinoid N-retinyl-N- retinylidene ethanolamine (A2E), which is a major component of lipofuscin, plays an important role in RPE death. In addition to what has been mentioned, in Stargardt disease, lipofuscin-accumulated RPE cells display increased activity of C3 complement, and as there is a negative correlation between C3 and CD46 levels, the inhibition of the complement cascade decreases. This promotes the formation of membrane attack complex (MAC) on the surface of RPE and leads to RPE death.[38] Progressive reduction of visual function and photoreceptor death occur due to RPE atrophy, which occurs due to epoxides formation with blue light exposure in patients with Stargardt disease.[15] Exposure to light, especially ultraviolet (UV) light, and high doses of vitamin A accelerate the progression of Stargardt disease.[39–42] A large amount of allelic heterogeneity has been reported in the ABCA4 gene; over 800 different mutations were mapped on the ABCA4 gene in Stargardt disease, which causes various phenotypes and multiple severities of the disease.[43–45] The age of onset is a prognostic factor; patients with lower age of onset (early-onset) will experience more severe disease.[8] The typical presentation of Stargardt disease is bilateral progressive central vision loss, including central scotoma and decreased visual acuity.[43] Collison and Fishman[46] evaluated the visual acuity of 221 Stargardt patients aged >40 years; visual acuity decreased from the 20/200 to 20/400 or less, although none of the participants experienced profound visual loss. The typical clinical findings in Stargardt disease are central macular atrophy and irregular yellowish–white fundus flecks in the posterior pole at the RPE level; the appearance of the fundus could vary.[39, 47–49] Stem cells are a valuable resource of tissue transplantation due to their unlimited proliferation and their capacity to generate multiple cell lineages.[50] Due to the low immunogenicity of stem cells, including embryonic or pluripotent stem cells (PSCs), the chance of transplantation rejection is low.[51] Different sources of stem cells including human embryonic stem cell (hESC), induced pluripotent stem cells (iPSC), mesenchymal stem cell (MSC), and neural stem cells (NSCs) are available.[18, 52] hESCs and iPSCs are PSCs, which are derived from blastocysts and somatic cells, respectively.[53, 54] Teratoma formation, cancer formation, immune rejection of the transplanted tissue, and differentiation of stem cells into unwanted ectopic cell types are the most critical safety concerns regarding hESC transplantation in humans.[21, 55] Embryonic stem cells (ESCs) have immune rejection potential, and there are also ethical issues in using these cells; therefore, iPSCs are preferred for clinical application.[56] Due to the potential immune response or immune rejection of hESCs, topical or systemic immune suppression is required in the transplantation of hESCs.[57] MSCs are stromal cells with multilineage differentiation ability that can be isolated from different sources, including bone marrow, adipose tissue, umbilical cord, endometrial polyp, and menses blood.[58] MSCs have the ability to migrate and differentiate into the injured tissues, which is called homing ability. Furthermore, MSCs have immunomodulatory effects such as preventing the function and proliferation of T cells, B cells, and natural killer cells.[58, 59] The low immunogenicity of MSCs is due to 320 JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al Table 1. Characteristics and outcomes of interventional studies that evaluated stem cell therapy for Stargardt disease. Author and publication year Country Study design Human VS animal Participants Method Stem cell type Efficacy Complications Quality Assessment Score (GRADE) 2023 Rodrigo A Brant Fernandes et al[13] Brazil (Phase 1 clinical trial) Non- randomized interventional clinical trial Human study 12 eyes from 12 participants Subretinal hESC No significant improvement in BCVA was found No complications were found Very low 2021 Shi-Yung Li et al[14] China (Phase 1 clinical trial) Non- randomized interventional clinical trial Human study 7 eyes from 7 participants Subretinal hESC No significant improvement was found except in one patient High postoperative intraocular pressure in two eyes Very low 2021 Jeffrey N Weiss et al[15] USA Open label, Non-randomized interventional clinical trial Human study 34 eyes from 17 participants Retrobulbar, subtenons, intravitreal, subretinal and intravenous Autologous bone marrow- derived stem cell The visual acuity improved in 21 eyes with the mean improvement of +0.4095 logMAR, or 4.29 lines of vision No complications were found Very low 2021 Youngje Sung et al[16] Republic of Korea Non-randomized interventional clinical trial Human study 3 eyes Subretinal hESC The visual acuity significantly improved in an eye with 19 ETDRS letters BCVA improvement Retinal detachment in one eye Very low 2020 Carina Costa Cotrim et al[17] Brazil Open label, Non-randomized interventional clinical trial Human study 10 eyes Intravitreal Bone marrow mononuclear fraction with CD34+ cells The mean of visual acuity improved from 1.1 logMAR to 0.96, 0.92, and 0.98 logMAR at 1, 3, and 6 months after IV injection, respectively No complications were found Very low 2018 Ayse Oner et al[18] Turkey (Phase 1/2 clinical trial) Non- randomized interventional clinical trial Human study 4 eyes Suprachoroidal Adipose tissue-derived mesenchymal stem cell Visual acuity and visual field improvement in all participants. The mean BCVA improved from 1.52 logMAR to 1.02 logMAR No complications were found Very low 2018 Manjit S Mehat et al[19] UK (Phase 1/2 clinical trial) Open-label, Non- randomized interventional clinical trial Human study 12 eyes Subretinal hESC No significant benefits were found at 12 months Small subretinal hemorrhage in two eyes and mild vitreous cavity hemorrhage in one eye. Very low 2016 Ella H Leung et al[20] USA Case Report Human study 1 eye Subretinal Autologous bone marrow- derived stem cell Visual acuity improved from 1.3 logMAR (20/400) to 1.2 logMAR (20/300) Temporary retinal detachment and proliferative vitreoretinopathy Very low 2015 Steven D Schwaretz et al[21] USA (Phase 1/2 clinical trial) Non- randomized interventional clinical trial Human study 9 eyes Subretinal hESC No significant improvement. Visual acuity insignificantly improved in three eyes at twelve months Acute vitreous endophthalmitis in one eye and three eyes developed cataracts Very low 2015 Won Kyung Song et al[22] Republic of Korea Non-randomized interventional clinical trial Human study 2 eyes Subretinal hESC Visual acuity improved with the mean of 15.5 ETDRS. patient one from counting finger to 1.5 logMAR, patient 2 from 1.5 to 1.1 logMAR No complications were found Very low 2012 Steven D Schwartz et al[23] USA (Preliminary report) Non- randomized interventional clinical trial Human study 1 eye Subretinal hESC Visual acuity improved from hand motion (0 ETDRS) to 1.6 logMAR (5 ETDRS) No complications were found Very low 2012 Katherine J Wert et al[24] USA Animal interventional study Animal Study One postnatal day five mice Subretinal Mouse embryonic stem cell BCVA was not determined Presence of stem cells in 15 weeks mouse Temporary retinal detachment Very low 2009 Bin Lu et al[25] USA Animal interventional study Animal study The RCS rat, Elov14 mouse, and the NIH III immune- deficient mouse model Subretinal hESC Treated eyes with stem cell injection had significantly better visual acuity than control eyes with sham injection. Details of visual acuity were not determined No complications were found Very low hESC, human embryonic stem cell; GRADE, Grading of Recommendations, Assessment, and Evaluation JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 321 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al Records identified by Databases searching (n = 179) PubMed: 108 Scopus: 71 Records removed before screening: Duplicate records removed (n = 43) Identification of studies via databases Id e n ti fi c a ti o n Records screened (title/abstract) (n = 136) Records excluded after screening of title/abstract (n = 78) Full-texts assessed for eligibility (n = 58) Reports excluded with reason: (n = 45) No assessment of stem cell therapy in Stargardt disease, other types of macular degeneration (except Stargardt), duplications, and reviews or non-clinical trial articles Studies included in review (n = 13) Human clinical trials: 11 Animal clinical trials: 2 S c re e n in g In c lu d e d E li g ib il it y Figure 1. PRISMA flow diagram of search steps and designs. low HLA class І levels and the absence of HLA class ІІ expression.[60] These features make MSCs an appropriate candidate for stem cell transplantation. MSCs include bone marrow MSCs (BMMSCs) and adipose tissue-derived MSCs (ADMSCs). There are advantages in using ADMSCs as compared to BMMSCs, such as higher immunomodulatory effects and easier harvest.[18] There are three main routes for stem cell delivery in retinal degeneration: subretinal, suprachoroidal, and intravitreal injections. Most studies have chosen the subretinal injection method for stem cell transplantation.[15, 16, 19–25] Subretinal space is an immune-privileged site; with a reduced chance of transplantation rejection.[61, 62] RPE suppresses T cell activation by secreting cytokines, such as transforming growth factor β, thrombospondin- 1, Prostaglandin E2, cytotoxic T lymphocyte- associated antigen 2α, and retinoic acid.[61] In addition, RPE converts intraocular T cells into regulatory T cells by secretion of cytotoxic T lymphocyte-associated antigen 2 (CTLA-2α).[63] In the subretinal approach, the injection is performed in the transition zone, which is between the atrophic and fairly healthy retina.[21, 64] Due to the immune-privileged subretinal space, rejection occurs without obvious inflammatory infiltration, which is followed by cell loss and progressive function loss.[21, 65] Retinal detachment and retinal perforation are the most reported adverse events related to the subretinal approach.[16, 20, 24, 66, 67] In the suprachoroidal method, no violation of the vitreous cavity is performed, which is an advantage 322 JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al of this method.[18] Intravitreal transplantation of stem cells is the easiest route, and the safety of this method has been already shown in patients with atrophic age-related macular degeneration (AMD).[68] Animal studies have shown acceptable results of human RPE stem cell transplantation in retinal degenerative diseases.[69] Lu and colleagues[25] showed the long-term safety of hESC-derived RPE cells in immune-deficient mice. Furthermore, they showed the long-term function of hESC-derived RPE in the both Elov14 mouse and Royal College of Surgeons (RCS) rats which are animal models of Stargardt and AMD, respectively. The hESC- derived RPE survived for more than eight months in RCS rats without any pathological findings, including teratoma or tumor formation in subretinal transplantation. Elov14 mouse eyes that were treated with stem cell injection had significantly better visual acuity than control eyes treated with sham injection.[25] Animal models, especially mouse models, have been investigated for several years to find the potential treatments for retinal degenerative diseases such as Stargardt disease, AMD, and retinitis pigmentosa.[70, 71] Although Wert et al[24] reported temporary retinal detachment as a possible adverse event of the subretinal delivery method, no teratoma formation or immune rejection of transplanted tissue was found in animal models with Stargardt disease in stem cell therapy.[24, 25] Considering the promising results of stem cell therapy in animal models, human studies were pursued. In 2012, the subretinal injection of hESC was performed in one eye from a patient with Stargardt disease, and the patient was followed for four months; no signs of hyperproliferation, ectopic tissue formation, or immune-mediated transplant rejection was found during the follow- up period. Transplanted hESC-RPE attached to Bruch’s membrane and persisted during the follow- up period.[23] The patient’s vision improved from central hand motion (0 ETDRS letter) to five ETDRS letters, best-corrected visual acuity (BCVA) of 20/800 at 1one, two, and three months. Furthermore, improved color vision and contrast sensitivity and dark adaptation were reported subjectively by the patient.[23] In 2015, subretinal hESC transplantation was performed in two Asian patients;[22] no complications were reported. No evidence of adverse proliferation, tumorigenicity, or ectopic tissue formation was found during the follow-up period, which confirmed the safety of hESC-derived RPE.[22] After a year of follow-up, the visual acuity in the treated eyes improved by 12 ETDRS letters (from counting fingers at 2 feet to 20/640) in the first patient and 19 ETDRS letters (from 20/640 to 20/250) in the second patient.[22] In 2015, a study by Schwartz et al[21] evaluated subretinal transplantation of hESC-derived RPE in nine Stargardt disease patients.[21] They did not find any complications related to the transplanted tissue, such as adverse proliferation, immune rejection, or any kinds of safety issues, which indicated the long-term safety and graft survival of pluripotent stem cell transplantation.[21] In their study, one eye developed inflammation in the vitreous cavity with acute vitreous culture-positive (Staphylococcus Epidermidis) endophthalmitis, however, they found no sign of infection in the subretinal space (hESC-RPE gram stain). Furthermore, three operated eyes developed cataracts in the follow-up period. From nine treated eyes, seven had a 12-month assessment; among them, the visual acuity improved in three eyes.[21] Although in five eyes ,which did not develop cataracts, the median of visual acuity was improved to 12 letters at the 12 month follow-up, the improvement was not significant between operated versus fellow eyes.[21] In 2016, Leung et al[20] reported subretinal autologous bone marrow-derived stem cells transplantation in a patient with Stargardt disease; the visual acuity improved from 20/400 to 20/300. They found macula-involving retinal detachment two months after subretinal stem cell injection and recurrent retinal detachment with proliferative vitreoretinopathy four months after subretinal stem cell injection, which could suggest potential complications of the subretinal method.[20] In 2018, Mehat et al[19] reported subretinal transplantation of hESC in 12 patients with Stargardt disease; no adverse proliferation or acute immune rejection was found. They reported a small subretinal hemorrhage at the injection site in two participants and mild vitreous cavity hemorrhage in one participant, furthermore in the hyperpigmentation area, localized retinal thinning and decreased sensitivity were reported.[19] Borderline improvement of BCVA was found in four participants, although the improvement JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 323 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al was not sustained or matched to the control contralateral eye; no significant benefits were detected after 12 months of assessment.[19] Oner et al[18] reported the suprachoroidal transplantation of AD-MSCs in four participants with Stargardt disease; after six months of the follow-up period, no ocular or systemic complication was found. Improvement of BCVA was experienced by all participants in this study. Furthermore, all participants experienced visual field improvement on Goldmann perimetry.[18] Cotrim et al[17] reported intravitreal transplantation of bone marrow mononuclear fraction containing CD34+ cells in 10 patients with Stargardt disease. During the six months of follow-up, no complications such as infection, retinal detachment, or tumor formation was found. In the eye with intravitreal injection, the mean of baseline visual acuity was 1.1 logMAR at baseline which improved to 0.96, 0.92, and 0.98 logMAR, at one, three, and six months after intravitreal injection, respectively. In the eye with the sham injection, the mean of visual acuity at baseline was 1.0 logMAR which improved to 0.96, 0.94, and 0.96 at one, three, and six months, respectively. Their results showed a significant difference in the treated eye at all of the follow-up times.[17] Sung et al[16] published a study on subretinal transplantation of hESCs in three Stargardt disease patients. Their findings suggested the long-term safety of subretinal transplantation of hESC-derived RPE cells; however, they noticed rhegmatogenous retinal detachment in one of the participants 19 weeks after the subretinal hESC transplantation.[16] After three years of follow-up, visual acuity improved 9, 19, and 6 ETDRS letters in the first, second, and third patient, respectively; compared to the fellow eye, visual acuity improved in the second patient and remained stable in the other two patients.[16] Four weeks after the transplantation, subretinal pigmentation was observed and increased until six weeks and then remained stable during three years’ follow-up.[16] Weiss et al[15] evaluated the results of retrobulbar, subtenon, intravitreal, subretinal, and intravenous autologous bone marrow-derived stem cells transplantation in 34 eyes from 17 patients with Stargardt disease. The visual acuity improved in 21 eyes (with the average visual acuity improvement of 33.3% or with the mean logMAR improvement of +0.4095), remained stable in 8 eyes, and decreased in 5 eyes after one year, and no surgical complications were found.[15] They found no significant difference in the efficacy of multiple delivery methods.[15] Li et al[14] reported the five-year follow-up of subretinal hESC-RPE transplantation in seven Stargardt disease patients. High postoperative intraocular pressure (ranging from 26 to 32 mm Hg) was observed in two participants 1– 2 months after the operation, although it was controlled by medications and silicone oil removal; none of the participants experienced retinal detachment, immune reaction, endophthalmitis, or tumor formation during the 5-year follow-up.[14] Although the visual function of all participants remained stable or improved at four months after the operation, there was no significant difference between the operated and the fellow eye regarding visual acuity, pattern visual evoked potential (PVEP), and full-field electroretinography (ffERG) after five years of the follow-up period, except in one participant.[14] Recently, Brant Fernandes et al[13] evaluated the subretinal transplantation of hESC-RPE in 12 eyes diagnosed with advanced Stargardt disease. After a 12-month follow-up, their results showed no significant increase in BCVA in the treated eyes, and they found no adverse events during the follow-up period such as ocular or systemic tumor development, cellular migration, corneal edema, ocular or systemic inflammation, endophthalmitis, ocular bleeding, retinal detachment, elevation of intraocular pressure, or transplantation rejection.[13] The subretinal approach has been assessed by most studies; retinal detachment and retinal perforation are reported as adverse complications of this approach. Studies have isolated and characterized the RPE cells from different stem cell types. Most studies evaluated hESC; however, there might be long-term safety issues including potential immune response or rejection, the ability of tumor formation, and adverse tissue formation or proliferation. On the other hand, some studies reported unsustained improvement in visual acuity which is one of the challenges of stem cell therapy in Stargardt disease.[14, 19] Currently, cell therapy is not FDA-approved for Stargardt disease; studies are ongoing to determine the best method of therapy for this disease. Although the quality of evidence of studies included in this systematic review was assessed as very low, the research in this field is nascent and most investigations are 324 JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al pilot studies or phase 1/2 RCTs. Considering the promising results of these novel approaches, future studies with improved quality of evidence may determine the best stem cell type and the preferred delivery method. This study has some limitations. The sample size was small in retrieved studies and was not enough to evaluate the safety and efficacy of stem cell therapy in Stargardt disease. Also, the follow- up period varied in different studies. Due to high heterogeneity among studies in various stem cell types and delivery methods, we were unable to perform a meta-analysis. Adding other databases and involving other languages in the primary search may increase the number of studies. CONCLUSION In conclusion, stem cell therapy has the potential to improve the visual function of patients with Stargardt disease. Although several studies have suggested benefits of stem cell therapy for Stargardt disease, further RCTs are needed to determine the long-term safety and efficacy of stem cell therapy in Stargardt disease. Further investigation is also needed to choose the best delivery method and stem cell type. Financial Support and Sponsorship None. Conflicts of Interest None. REFERENCES 1. Ricca AM, Han IC, Sohn EH. Stargardt disease masquerades. Curr Opin Ophthalmol 2021;32:214–224. 2. Stone EM, Andorf JL, Whitmore SS, DeLuca AP, Giacalone JC, Streb LM, et al. Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease. Ophthalmology 2017;124:1314–1331. 3. Haddley K. Stargardt disease: Light at the end of the tunnel. Drugs Future 2011;36:527–533. 4. Sears AE, Bernstein PS, Cideciyan AV, Hoyng C, Charbel Issa P, Palczewski K, et al. Towards treatment of Stargardt disease: Workshop organized and sponsored by the foundation fighting blindness. Transl Vis Sci Technol 2017;6:6. 5. Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: Recent advancements and treatment. Semin Ophthalmol 2013;28:372–376. 6. Khan M, Cremers FP. ABCA4-associated Stargardt disease. Klin Monatsbl Augenheilkd 2020;237:267–274. 7. Jonsson F, Westin IM, Österman L, Sandgren O, Burstedt M, Holmberg M, et al. ATP-binding cassette subfamily A, member 4 intronic variants c.4773+3A>G and c.5461- 10T>C cause Stargardt disease due to defective splicing. Acta Ophthalmol 2018;96:737–743. 8. Tsang SH, Sharma T. Stargardt disease. Adv Exp Med Biol 2018;1085:139–51. 9. Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther 2018;18:1049–1059. 10. Battu R, Ratra D, Gopal L. Newer therapeutic options for inherited retinal diseases: Gene and cell replacement therapy. Indian J Ophthalmol 2022;70:2316–2325. 11. Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, et al. The natural history of the progression of atrophy secondary to Stargardt Disease (ProgStar) Studies: Design and baseline characteristics: ProgStar report no. 1. Ophthalmology 2016;123:817–828. 12. Jin ZB, Gao ML, Deng WL, Wu KC, Sugita S, Mandai M, et al. Stemming retinal regeneration with pluripotent stem cells. Prog Retin Eye Res 2019;69:38–56. 13. Brant Fernandes RA, Lojudice FH, Zago Ribeiro L, Santos da Cruz NF, Polizelli MU, Cristovam PC, et al. Transplantation of subretinal stem cell-derived retinal pigment epithelium for Stargardt disease: A phase I clinical trial. Retina 2023;43:263–274. 14. Li SY, Liu Y, Wang L, Wang F, Zhao TT, Li QY, et al. A phase I clinical trial of human embryonic stem cell- derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years’ follow-up. Cell Prolif 2021;54:e13100. 15. Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study (SCOTS): Bone marrow-derived stem cells in the treatment of Stargardt disease. Medicines 2021;8:10. 16. Sung Y, Lee MJ, Choi J, Jung SY, Chong SY, Sung JH, et al. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol 2021;105:829–837. 17. Cotrim CC, Vieira Messias AM, Jorge R, Siqueira RC. Intravitreal use of a bone marrow mononuclear fraction (BMMF) containing CD34+ cells in patients with Stargardt type macular dystrophy. Stem Cells Int 2020;2020:8828256. 18. Oner A, Gonen ZB, Sevim DG, Smim Kahraman N, Unlu M. Suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with dry-type age- related macular degeneration and Stargardt’s macular dystrophy: 6-month follow-up results of a phase 2 study. Cell Reprogram 2018;20:329–336. 19. Mehat MS, Sundaram V, Ripamonti C, Robson AG, Smith AJ, Borooah S, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology 2018;125:1765–1775. 20. Leung EH, Flynn HW Jr, Albini TA, Medina CA. Retinal detachment after subretinal stem cell transplantation. Ophthalmic Surg Lasers Imaging Retina 2016;47:600–601. 21. Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, et al. Human embryonic stem cell-derived JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 325 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: Follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509–516. 22. Song WK, Park KM, Kim HJ, Lee JH, Choi J, Chong SY, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: Preliminary results in Asian patients. Stem Cell Rep 2015;4:860–872. 23. Schwartz SD, Hubschman JP, Heilwell G, Franco- Cardenas V, Pan CK, Ostrick RM, et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012;379:713–720. 24. Wert KJ, Skeie JM, Davis RJ, Tsang SH, Mahajan VB. Subretinal injection of gene therapy vectors and stem cells in the perinatal mouse eye. J Vis Exp 2012;69:4286. 25. Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells 2009;27:2126–2135. 26. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 27. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–394. 28. Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. Clin Exp Ophthalmol 2021;49:498–515. 29. Walia S, Fishman GA. Natural history of phenotypic changes in Stargardt macular dystrophy. Ophthalmic Genet 2009;30:63–68. 30. Palejwala NV, Gale MJ, Clark RF, Schlechter C, Weleber RG, Pennesi ME. Insights into autosomal dominant Stargardt-like macular dystrophy through multimodality diagnostic imaging. Retina 2016;36:119–130. 31. Donoso LA, Edwards AO, Frost A, Vrabec T, Stone EM, Hageman GS, et al. Autosomal dominant Stargardt-like macular dystrophy. Surv Ophthalmol 2001;46:149–163. 32. Vasireddy V, Wong P, Ayyagari R. Genetics and molecular pathology of Stargardt-like macular degeneration. Prog Retin Eye Res 2010;29:191–207. 33. Schulz HL, Grassmann F, Kellner U, Spital G, Rüther K, Jägle H, et al. Mutation spectrum of the ABCA4 gene in 335 Stargardt disease patients from a multicenter german cohort-impact of selected deep intronic variants and common SNPs. Invest Ophthalmol Vis Sci 2017;58:394– 403. 34. Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: Structural and functional properties and role in retinal disease. Adv Exp Med Biol 2010;703:105–125. 35. Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol 2017;255:1057–1062. 36. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595–606. 37. Parmar VM, Parmar T, Arai E, Perusek L, Maeda A. A2E-associated cell death and inflammation in retinal pigmented epithelial cells from human induced pluripotent stem cells. Stem Cell Res 2018;27:95–104. 38. Ng ES, Kady N, Hu J, Dave A, Jiang Z, Pei J, et al. Membrane attack complex mediates retinal pigment epithelium cell death in Stargardt macular degeneration. Cells 2022;11:3462. 39. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: Clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol 2017;101:25–30. 40. Chen Y, Okano K, Maeda T, Chauhan V, Golczak M, Maeda A, et al. Mechanism of all-trans-retinal toxicity with implications for Stargardt disease and age-related macular degeneration. J Biol Chem 2012;287:5059–5069. 41. Radu RA, Mata NL, Bagla A, Travis GH. Light exposure stimulates formation of A2E oxiranes in a mouse model of Stargardt’s macular degeneration. Proc Natl Acad Sci USA 2004;101:5928–5933. 42. Teussink MM, Lee MD, Smith RT, van Huet RA, Klaver CC, Klevering BJ, et al. The effect of light deprivation in patients with Stargardt disease. Am J Ophthalmol 2015;159:964–972.e2. 43. Fujinami K, Strauss RW, Chiang JP, Audo IS, Bernstein PS, Birch DG, et al. Detailed genetic characteristics of an international large cohort of patients with Stargardt disease: ProgStar study report 8. Br J Ophthalmol 2019;103:390–397. 44. Lee W, Xie Y, Zernant J, Yuan B, Bearelly S, Tsang SH, et al. Complex inheritance of ABCA4 disease: Four mutations in a family with multiple macular phenotypes. Hum Genet 2016;135:9–19. 45. Arrigo A, Grazioli A, Romano F, Aragona E, Bordato A, di Nunzio C, et al. Choroidal patterns in Stargardt disease: Correlations with visual acuity and disease progression. J Clin Med 2019;8:1388. 46. Collison FT, Fishman GA. Visual acuity in patients with Stargardt disease after age 40. Retina 2018;38:2387– 2394. 47. Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, et al. ABCA4 gene screening by next-generation sequencing in a British cohort. Invest Ophthalmol Vis Sci 2013;54:6662–6674. 48. Lambertus S, van Huet RA, Bax NM, Hoefsloot LH, Cremers FP, Boon CJ, et al. Early-onset Stargardt disease: Phenotypic and genotypic characteristics. Ophthalmology 2015;122:335–344. 49. Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology 2015;122:326–334. 50. Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: Past, present and future. Development 2013;140:2576–2585. 51. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013;494:100–104. 52. Mead B, Berry M, Logan A, Scott RA, Leadbeater W, Scheven BA. Stem cell treatment of degenerative eye disease. Stem Cell Res 2015;14:243–257. 53. Klimanskaya I, Hipp J, Rezai KA, West M, Atala A, Lanza R. Derivation and comparative assessment of retinal pigment epithelium from human embryonic stem cells 326 JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 Stem Cell Therapy in Stargardt Disease; Moghadam Fard et al using transcriptomics. Cloning Stem Cells 2004;6:217– 245. 54. Ahmed I, Johnston RJ Jr, Singh MS. Pluripotent stem cell therapy for retinal diseases. Ann Transl Med 2021;9:1279. 55. Maeda A, Mandai M, Takahashi M. Gene and induced pluripotent stem cell therapy for retinal diseases. Annu Rev Genomics Hum Genet 2019;20:201–216. 56. Han F, Xu G. Stem cell transplantation therapy for retinal degenerative diseases. Adv Exp Med Biol 2020;1266:127– 139. 57. Sharma A, Jaganathan BG. Stem cell therapy for retinal degeneration: The evidence to date. Biologics 2021;15:299–306. 58. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant 2011;20:5–14. 59. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells 2019;8:784. 60. Lin Y, Ren X, Chen Y, Chen D. Interaction between mesenchymal stem cells and retinal degenerative microenvironment. Front Neurosci 2021;14:617377. 61. Xian B, Huang B. The immune response of stem cells in subretinal transplantation. Stem Cell Res Ther 2015;6:161. 62. Streilein JW, Ma N, Wenkel H, Ng TF, Zamiri P. Immunobiology and privilege of neuronal retina and pigment epithelium transplants. Vision Res 2002;42:487– 495. 63. Sugita S, Horie S, Nakamura O, Maruyama K, Takase H, Usui Y. Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions. J Immunol 2009;183:5013–5022. 64. Raimondi R, Zollet P, De Rosa FP, Tsoutsanis P, Stravalaci M, Paulis M, et al. Where are we with RPE replacement therapy? A translational review from the ophthalmologist perspective. Int J Mol Sci 2022;23:682. 65. Grisanti S, Szurman P, Jordan J, Kociok N, Bartz- Schmidt KU, Heimann K. Xenotransplantation of retinal pigment epithelial cells into RCS rats. Jpn J Ophthalmol 2002;46:36–44. 66. Ho AC, Chang TS, Samuel M, Williamson P, Willenbucher RF, Malone T. Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol 2017;179:67–80. 67. Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: A review of clinical trials and direct to consumer “cell therapy” clinics. Stem Cell Res Ther 2021;12:538. 68. Cotrim CC, Toscano L, Messias A, Jorge R, Siqueira RC. Intravitreal use of bone marrow mononuclear fraction containing CD34+ stem cells in patients with atrophic age-related macular degeneration. Clin Ophthalmol 2017;11:931–938. 69. Luo M, Chen Y. Application of stem cell-derived retinal pigmented epithelium in retinal degenerative diseases: Present and future. Int J Ophthalmol 2018;11:150–159. 70. Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR. Retinal degeneration mutants in the mouse. Vision Res 2002;42:517–525. 71. Won J, Shi LY, Hicks W, Wang J, Hurd R, Naggert JK, et al. Mouse model resources for vision research. J Ophthalmol 2011;2011:391384. JOURNAL OF OPHTHALMIC AND VISION RESEARCH Volume 18, Issue 3, July-Sept 2023 327